Editorial Comment from Dr Xu and Dr Wei to Murine double minute 2 promoter SNP309 polymorphism and prostate cancer risk: A meta-analysis.
Summary of "Editorial Comment from Dr Xu and Dr Wei to Murine double minute 2 promoter SNP309 polymorphism and prostate cancer risk: A meta-analysis."
No Summary Available
Department of Urology, Affiliated Wuxi People's Hospital, Nanjing Medical University, Wuxi, China. firstname.lastname@example.org or email@example.com.
This article was published in the following journal.
Name: International journal of urology : official journal of the Japanese Urological Association
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22715898
- DOI: http://dx.doi.org/10.1111/j.1442-2042.2012.03081.x
Medical and Biotech [MESH] Definitions
Work consisting of a critical or explanatory note written to discuss, support, or dispute an article or other presentation previously published. It may take the form of an article, letter, editorial, etc. It appears in publications under a variety of names: comment, commentary, editorial comment, viewpoint, etc.
The guidelines and policy statements set forth by the editor(s) or editorial board of a publication.
Abelson Murine Leukemia Virus
A replication-defective strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) capable of transforming lymphoid cells and producing a rapidly progressing lymphoid leukemia after superinfection with FRIEND MURINE LEUKEMIA VIRUS; MOLONEY MURINE LEUKEMIA VIRUS; or RAUSCHER VIRUS.
Kirsten Murine Sarcoma Virus
A replication-defective murine sarcoma virus (SARCOMA VIRUSES, MURINE) capable of transforming mouse lymphoid cells and producing erythroid leukemia after superinfection with murine leukemia viruses (LEUKEMIA VIRUS, MURINE). It has also been found to transform cultured human fibroblasts, rat liver epithelial cells, and rat adrenocortical cells.
Sarcoma Viruses, Murine
A group of replication-defective viruses, in the genus GAMMARETROVIRUS, which are capable of transforming cells, but which replicate and produce tumors only in the presence of Murine leukemia viruses (LEUKEMIA VIRUS, MURINE).
Objective: The murine double minute 2 gene encodes a negative regulator of the tumor protein p53. A single nucleotide polymorphism in murine double minute 2 promoter, SNP309 T>G, has been reported...
BACKGROUND AND AIMS: The murine double minute 2 (MDM2) gene encodes a negative regulator of the tumour protein p53. A single nucleotide polymorphism (SNP) in MDM2 promoter, SNP309 T > G, has been sh...
The incidence of endometrial cancer, a common gynecological malignancy, is increasing in Japan. We have previously shown that the ER/MDM2/p53/p21 pathway plays an important role in endometrial carcino...
A single-nucleotide polymorphism in the MDM2 promoter (SNP309; rs2279744) causes elevated transcription of this major negative regulator of p53 in several cancer types. We investigated MDM2 SNP309 and...
In human cells, endogenous TRIM5alpha strongly inhibits N-tropic strains of murine leukemia virus (N-MLV) but does not target the closely related B-MLV. We have used a shRNA-based loss-of-function scr...
MOA-728, an investigational drug, is currently being studied for the relief of constipation associated with postoperative ileus and treatment of opioid induced constipation in patients rec...
CENTRIC is a Phase III clinical trial assessing efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment versus standard treatment...
CORE is a Phase II clinical trial in newly diagnosed glioblastoma multiforme (GBM) in patients with an unmethylated promoter of the methylguanine-DNA methyltransferase (MGMT) gene in the t...
Polymorphisms of HSP70 and tumor necrosis factor-alpha promoter in patients with hepatocellular carcinoma, chronic liver disease and healthy controls will be measured by PCR-RFLP or direct...
Subjects will receive six months of DBT, consisting of one 90-minute group and one 60-minute individual session per week as well as telephone availability of the individual therapist. Half...